RWDD4: Regulating Cell Growth and Differentiation (G201965)

Target Name: RWDD4

NCBI ID: G201965

RWDD4

RWDD4: Regulating Cell Growth and Differentiation

RWDD4 (RWDD4 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, kidneys, and liver. It is a member of the superfamily of proteins known as the FERMTAT family, which includes proteins that are involved in cell signaling and division.

One of the unique features of RWDD4 is its ability to interact with the protein p180G, which is also known as activator protein 1 (AP-1). Activator protein 1 is a transmembrane protein that is involved in various signaling pathways, including the cell division cycle and the regulation of cell growth.

RWDD4 has been shown to play a role in the regulation of cell growth and differentiation. It has been shown to inhibit the activity of activator protein 1, which can lead to the inhibition of cell growth and the promotion of cell differentiation.

Another unique feature of RWDD4 is its ability to interact with the protein p53, which is a tumor suppressor protein. p53 is a transmembrane protein that is involved in the regulation of various cellular processes, including DNA replication and apoptosis (programmed cell death).

RWDD4 has been shown to play a role in the regulation of p53 activity. It has been shown to enhance the activity of p53, which can lead to the inhibition of cell growth and the promotion of cell apoptosis.

In conclusion, RWDD4 is a protein that is involved in the regulation of cell growth and differentiation. It has been shown to interact with the protein p180G and p53, which are involved in various signaling pathways. Further research is needed to fully understand the role of RWDD4 in cell signaling and development.

Protein Name: RWD Domain Containing 4

The "RWDD4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RWDD4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets